CG Oncology (NASDAQ:CGON – Get Free Report) and MediWound (NASDAQ:MDWD – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.
Risk & Volatility
CG Oncology has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Comparatively, MediWound has a beta of 0.09, indicating that its share price is 91% less volatile than the S&P 500.
Valuation & Earnings
This table compares CG Oncology and MediWound”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CG Oncology | $4.04 million | 1,369.09 | -$160.99 million | ($2.69) | -23.20 |
| MediWound | $16.96 million | 9.26 | -$23.88 million | ($1.80) | -6.79 |
MediWound has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and target prices for CG Oncology and MediWound, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CG Oncology | 1 | 1 | 8 | 0 | 2.70 |
| MediWound | 1 | 1 | 4 | 0 | 2.50 |
CG Oncology presently has a consensus price target of $87.50, indicating a potential upside of 40.22%. MediWound has a consensus price target of $33.00, indicating a potential upside of 170.05%. Given MediWound’s higher probable upside, analysts plainly believe MediWound is more favorable than CG Oncology.
Profitability
This table compares CG Oncology and MediWound’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CG Oncology | -3,602.68% | -25.20% | -23.98% |
| MediWound | -170.10% | -47.24% | -24.27% |
Institutional & Insider Ownership
26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
MediWound beats CG Oncology on 7 of the 13 factors compared between the two stocks.
About CG Oncology
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.
About MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
